TBThomas Bortfeld

Thomas Bortfeld

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Thomas Bortfeld has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • From optimization of radiation dose distributions to optimal cancer treatments

    by Thomas Bortfeld, Steve Webb

    The history of optimization in radiation oncology is closely intertwined with the history of Physics in Medicine & Biology ( PMB ). Over the past four decades, many of the conceptual advances that transformed radiotherapy—from forward planning to inverse planning, from physical to biological optimization, and from treatment planning to treatment strategy optimization—were first reported in the pages of this journal. Looking back from the perspective of PMB’s seventieth anniversary, one can trace a remarkably consistent intellectual trajectory: the progressive expansion of optimization from the design of radiation dose distributions to the optimization of entire cancer treatment pathways.

  • Open Access

    Bi-level Multi-criteria Optimization for Risk-informed Radiotherapy

    by Mara Schubert, Katrin Teichert, Zhongxing Liao, Thomas R Bortfeld, Ali Ajdari

    Objective: In radiation therapy (RT) treatment planning, multi-criteria optimization (MCO) allows physicians to find the best plan efficiently. MCO is conventionally solved for a set of generic (population-wide) dosimetric criteria, ignoring patient-specific biological risk factors and compromising clinical outcomes in high-risk groups. We propose a one-shot method - risk-guided MCO - for integration of biological risk factors within conventional MCO, enabling interactive plan navigation between dosimetric and biological endpoints. Approach: A cohort of non small cell lung cancer (NSCLC) patients receiving proton/photon RT was retrospectively analyzed. The clinical endpoint was the risk of symptomatic (grade 2+) radiation pneumonitis (RP), modeled using bootstrapped stepwise logistics regression (with interactions) accounting for baseline lung function, smoking history, and conventional dosimetric factors. We utilize an appropriately chosen order relation to fuse the conventional MCO sandwiching algorithm with bi- level optimization, restricting the (infinite) Pareto set to plans with substantial gain in the secondary risk objective for acceptable loss in primary (clinical) objectives. Thus, risk-guided MCO computes risk-optimized counterparts of clinical plans in a single run (rather than a sequential/lexicographic approach) within user-defined trade-offs. Performance was assessed in terms of clinical objectives and predicted RP risk. Main results: Across 19 patients, the risk-guided plans yielded an average reduction of 8.0 percentage points in total lung V20Gy and 9.5 percentage points in right lung Gy, translating into an average RP risk reduction of 7.7 percentage points (range=0.3%-20.1%), with small changes in target coverage (mean -1.2 D98[%] for CTV) and modest increase in heart dose (mean +1.74 Gy). Significance: This study presents the first proof-of-concept for integrating bio- logical risk models directly within multi-criteria RT planning, enabling an interactive balance between established population-wide dose protocols and individualized out- come prediction. Our results demonstrate that the risk-informed MCO can reduce the risk of RP while maintaining target coverage.

  • Evaluation of robust central nervous system treatment planning on a compact, gantry-less proton therapy system

    by Peter Jermain, Susu Yan, Helen Shih, Nicolas Depauw, Andrzej Niemierko, Thomas R Bortfeld

    Objective: This study assessed the clinical feasibility of robust treatment planning for central nervous system (CNS) tumors using a gantry-less proton therapy configuration, with the goal of supporting adoption of compact proton systems that are more affordable and accessible. Approach: Treatment plans for CNS cases were created in RayStation with three configurations: a full-gantry with the patient in a supine position, and a fixed, horizontal beamline with the patient either in a supine or seated position. Robust optimization was used for each plan, accounting for ±2mm isotropic setup errors and ±3.5% range uncertainties. To simulate potential impact of slouch, anisotropic setup shifts (±2, ±3, ±4mm) in the superior-inferior direction were evaluated for treatments in the seated position. A radiation oncologist conducted a blind review of the gantry-based and gantry-less plans to determine the preferred option. Dose metrics and robustness were compared across the different configurations, and statistical analyses were performed to assess the significance of any differences. In total, there were 10 cases, 50 treatment plans, and 1,050 treatment course scenarios. Main Results: Results showed that proton pencil beam scanning plans using a fixed horizontal beamline can produce comparable dosimetric outcomes to those utilizing a full-gantry. All three configurations achieved the required target coverage, with hotspots generally within 3-5% of the prescribed dose. In 8 out of 10 cases, the target homogeneity index was lowest in a gantry-less configuration. The gantry-based and gantry-less plans demonstrated similar robustness against setup errors and range uncertainties, though target coverage was slightly more robust in certain gantry or gantry-less plans, depending on the specific case and treatment configuration. Significance: By integrating blinded radiation oncologist assessment with quantitative dosimetric analysis, this work shows that fixed, horizontal proton beamlines can deliver high-quality plans, supporting the initial clinical feasibility of compact proton therapy systems.

  • Open Access

    Probabilistic clinical target definition with nearest neighbor correlation

    by L Rivetti, G Buti, L Amoudruz, A Ajdari, G Sharp, A Studen, R Jeraj, T Bortfeld

    Objective. The delineation of the clinical target volume (CTV) in radiotherapy is fundamentally uncertain due to the invisibility of microscopic disease on medical images. The ICRU 83 report acknowledges this by proposing a probabilistic interpretation of the CTV, but it does not define how to compute the probability of microscopic tumor presence (MTP) in tissue. This work addresses this gap by introducing a novel stochastic model that estimates the probability of MTP at the voxel level based on local spatial correlations in the voxels’ neighborhood. Approach. We developed two first-principles stochastic models to simulate MTP under different assumptions, incorporating spatial correlation between neighboring voxels. The constant marginal probability (CMP) model assumes spatially uniform MTP and is suited for tumors without radial dependence on the distance from the gross tumor volume (GTV). The variable marginal probability (VMP) model introduces radial dependence, modeling decreasing MTP with distance from the GTV. The CMP model was evaluated on prostate cancer data, while the VMP model was assessed using breast and lung cancer data. Results. Both models accurately reproduced the fraction of times that MTP is present. In the prostate case, the CMP model estimated a marginal probability of MTP of 0.03, consistent with a literature report that indicates an average total microscopic tumor volume of approximately 583 mm 3 across patients. The VMP model successfully replicated the radial distribution of tumor islets, achieving mean absolute errors of 0.01 mm and 0.011 mm for breast and lung cancer distance distributions, respectively. However, not all MTP characteristics could be fully captured by the models, and in some cases discrepancies with population based tumor characteristics remain. Significance. This work introduces a statistically consistent framework that enables a probabilistic definition of the CTV. The proposed models provide a new way to capture key aspects of microscopic disease spread by introducing local voxel correlations.


  • Open Access

    Inter-center comparison of proton range verification prototypes with an anthropomorphic head phantom

    by Fernando Hueso-González, Jonathan Berthold, Patrick Wohlfahrt, Thomas Bortfeld, Chirasak Khamfongkhruea, Sebastian Tattenberg, Melek Zarifi, Joost Verburg, Christian Richter

    Objective. To compare in reproducible and equalized conditions the performance of two independent proton range verification systems based on prompt gamma-ray detectors from two different proton therapy centers. Approach. An anthropomorphic head phantom with calibrated stopping power, serving as ground truth, was irradiated with comparable treatment plans, spot positions and energies in both facilities. Clinical beam current, tumor contour and dose were used. The absolute range measurement was compared to the expected value according to the ground truth. The statistical precision was assessed by repeating each measurement ten times. Sensitivity to relative range shifts was evaluated by introducing 2 mm and 5 mm plastic slabs on half of the field. Main results. The resulting absolute range accuracy was within 2.4 mm in all cases. Relative range shifts were detected with deviations lower than 14%. Significance. The performance of both systems was deemed worthy of clinical application for the detection of range deviations. This study represents the first comparison of independent prompt gamma-ray-based proton range verification systems under equalized conditions with realistic treatment fields and beam currents.


  • Open Access

    Breast imaging with an ultra-low field MRI scanner: a pilot study

    by Sheng Shen, Neha Koonjoo, Friderike K. Longarino, Leslie R. Lamb, Juan C. Villa Camacho, Torben P.P. Hornung, Stephen E. Ogier, Susu Yan, Thomas R. Bortfeld, Mansi A. Saksena, et al.

    Breast cancer screening is necessary to reduce mortality due to undetected breast cancer. Current methods have limitations, and as a result many women forego regular screening. Magnetic resonance imaging (MRI) can overcome most of these limitations, but access to conventional MRI is not widely available for routine annual screening. Here, we used an MRI scanner operating at ultra-low field (ULF) to image the left breasts of 11 women (mean age, 35 years ±13 years) in the prone position. Three breast radiologists reviewed the imaging and were able to discern the breast outline and distinguish fibroglandular tissue (FGT) from intramammary adipose tissue. Additionally, the expert readers agreed on their assessment of the breast tissue pattern including fatty, scattered FGT, heterogeneous FGT, and extreme FGT. This preliminary work demonstrates that ULF breast MRI is feasible and may be a potential option for comfortable, widely deployable, and low-cost breast cancer diagnosis and screening.


  • Open Access

    Embedding machine learning based toxicity models within radiotherapy treatment plan optimization

    by Donato Maragno, Gregory Buti, Ş. İlKer Birbil, Zhongxing Liao, Thomas Bortfeld, Dick Den Hertog, Ali Ajdari

    Objective. This study addresses radiation-induced toxicity (RIT) challenges in radiotherapy (RT) by developing a personalized treatment planning framework. It leverages patient-specific data and dosimetric information to create an optimization model that limits adverse side effects using constraints learned from historical data. Approach. The study uses the optimization with constraint learning (OCL) framework, incorporating patient-specific factors into the optimization process. It consists of three steps: optimizing the baseline treatment plan using population-wide dosimetric constraints; training a machine learning (ML) model to estimate the patient’s RIT for the baseline plan; and adapting the treatment plan to minimize RIT using ML-learned patient-specific constraints. Various predictive models, including classification trees, ensembles of trees, and neural networks, are applied to predict the probability of grade 2+ radiation pneumonitis (RP2+) for non-small cell lung (NSCLC) cancer patients three months post-RT. The methodology is assessed with four high RP2+ risk NSCLC patients, with the goal of optimizing the dose distribution to constrain the RP2+ outcome below a pre-specified threshold. Conventional and OCL-enhanced plans are compared based on dosimetric parameters and predicted RP2+ risk. Sensitivity analysis on risk thresholds and data uncertainty is performed using a toy NSCLC case. Main results. Experiments show the methodology’s capacity to directly incorporate all predictive models into RT treatment planning. In the four patients studied, mean lung dose and V20 were reduced by an average of 1.78 Gy and 3.66%, resulting in an average RP2+ risk reduction from 95% to 42%. Notably, this reduction maintains tumor coverage, although in two cases, sparing the lung slightly increased spinal cord max-dose (0.23 and 0.79 Gy). Significance. By integrating patient-specific information into learned constraints, the study significantly reduces adverse side effects like RP2+ without compromising target coverage. This unified framework bridges the gap between predicting toxicities and optimizing treatment plans in personalized RT decision-making.


  • Our journeys through the fascinating world of proton radiation therapy

    by Thomas Bortfeld, Susu Yan

    The purpose of this article is to share the excitement of the science of proton therapy, told by two physicists, who started their career in this area at different times. The authors' journey spans the evolution of proton therapy over the past 30 years, taking the reader from the time when it was an extremely exotic treatment modality until its more common use today. Over this time period, the authors' research and development aimed at an improved understanding of the physical benefits of intensity‐modulated proton therapy and arc therapy, treatment planning and optimization to take proton‐specific uncertainties into account, and imaging to measure the proton range in the patient. The final section focuses on emerging themes to democratize proton therapy by substantially reducing its size and price, for much greater affordability and global availability of this treatment modality.


  • Open Access

    Modeling the propagation of tumor fronts with shortest path and diffusion models -- implications for the definition of the clinical target volume

    by Thomas Bortfeld, Gregory Buti

    Objective: The overarching objective is to make the definition of the clinical target volume (CTV) in radiation oncology less subjective and more scientifically based. The specific objective of this study is to investigate similarities and differences between two methods that model tumor spread beyond the visible gross tumor volume (GTV): 1. The shortest path model, which is the standard method of adding a geometric GTV-CTV margin, and 2. The reaction-diffusion model. Approach: These two models to capture the invisible tumor "fire front" are defined and compared in mathematical terms. The models are applied to example cases that represent tumor spread in non-uniform and anisotropic media with anatomical barriers. Main Results: The two seemingly disparate models bring forth traveling waves that can be associated with the front of tumor growth outward from the GTV. The shape of the fronts is similar for both models. Differences are seen in cases where the diffusive flow is reduced due to anatomical barriers, and in complex spatially non-uniform cases. The diffusion model generally leads to smoother fronts. The smoothness can be controlled with a parameter defined by the ratio of the diffusion coefficient and the proliferation rate. Significance: Defining the CTV has been described as the weakest link of the radiotherapy chain. There are many similarities in the mathematical description and the behavior of the common geometric GTV-CTV expansion method, and the definition of the CTV tumor front via the reaction-diffusion model. Its mechanistic basis and the controllable smoothness make the diffusion model an attractive alternative to the standard GTV-CTV margin model.

  • Modeling the propagation of tumor fronts with shortest path and diffusion models—implications for the definition of the clinical target volume

    by Thomas Bortfeld, Gregory Buti

    Objective. The overarching objective is to make the definition of the clinical target volume (CTV) in radiation oncology less subjective and more scientifically based. The specific objective of this study is to investigate similarities and differences between two methods that model tumor spread beyond the visible gross tumor volume (GTV): (1) the shortest path model, which is the standard method of adding a geometric GTV-CTV margin, and (2) the reaction-diffusion model. Approach. These two models to capture the invisible tumor ‘fire front’ are defined and compared in mathematical terms. The models are applied to example cases that represent tumor spread in non-uniform and anisotropic media with anatomical barriers. Main results. The two seemingly disparate models bring forth traveling waves that can be associated with the front of tumor growth outward from the GTV. The shape of the fronts is similar for both models. Differences are seen in cases where the diffusive flow is reduced due to anatomical barriers, and in complex spatially non-uniform cases. The diffusion model generally leads to smoother fronts. The smoothness can be controlled with a parameter defined by the ratio of the diffusion coefficient and the proliferation rate. Significance. Defining the CTV has been described as the weakest link of the radiotherapy chain. There are many similarities in the mathematical description and the behavior of the common geometric GTV-CTV expansion method, and the definition of the CTV tumor front via the reaction-diffusion model. Its mechanistic basis and the controllable smoothness make the diffusion model an attractive alternative to the standard GTV-CTV margin model.